{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T14:08:39Z","timestamp":1768399719610,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T00:00:00Z","timestamp":1485993600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s40261-017-0497-0","type":"journal-article","created":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T13:34:45Z","timestamp":1486042485000},"page":"465-472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults"],"prefix":"10.1007","volume":"37","author":[{"given":"Sara","family":"Armani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lillian","family":"Ting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Darstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anadya Prakash","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dung Yu","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi J","family":"Einolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swarupa","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,2]]},"reference":[{"key":"497_CR1","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing\u2019s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:2807\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"497_CR2","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1210\/jc.2011-3350","volume":"97","author":"M Fleseriu","year":"2012","unstructured":"Fleseriu M, Biller BM, Findling JW, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab. 2012;97:2039\u201349.","journal-title":"J Clin Endocrinol Metab"},{"key":"497_CR3","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2013-3628","volume":"99","author":"F Castinetti","year":"2014","unstructured":"Castinetti F, Guignat L, Giraud P, et al. Ketoconazole in Cushing\u2019s disease: is it worth a try? J Clin Endocrinol Metab. 2014;99:1623\u201330.","journal-title":"J Clin Endocrinol Metab"},{"key":"497_CR4","first-page":"OC6.5","volume":"34","author":"E Daniel","year":"2014","unstructured":"Daniel E, Aylwin S, Mustafa O, et al. Effectiveness of metyrapone in 195 patients with Cushing\u2019s syndrome. Endocrine Abstracts. 2014;34:OC6.5.","journal-title":"Endocrine Abstracts"},{"issue":"A61","key":"497_CR5","first-page":"E583","volume":"55","author":"J Menard","year":"2010","unstructured":"Menard J, Watson C, Rebello S, et al. Hormonal and electrolyte responses to the aldosterone synthase inhibitor LCI699 in sodium depleted healthy subjects. J Am Coll Cardiol. 2010;55(A61):E583.","journal-title":"J Am Coll Cardiol"},{"key":"497_CR6","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","volume":"56","author":"L Amar","year":"2010","unstructured":"Amar L, Azizi M, Menard J, et al. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension. 2010;56:831\u20138.","journal-title":"Hypertension"},{"key":"497_CR7","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","volume":"124","author":"DA Calhoun","year":"2011","unstructured":"Calhoun DA, White WB, Krum H, et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation. 2011;124:1945\u201355.","journal-title":"Circulation"},{"key":"497_CR8","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1210\/jc.2013-2117","volume":"99","author":"X Bertagna","year":"2014","unstructured":"Bertagna X, Pivonello R, Fleseriu M, et al. LCI699, a potent 11b-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing\u2019s disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab. 2014;99:1375\u201383.","journal-title":"J Clin Endocrinol Metab"},{"key":"497_CR9","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","volume":"19","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Pivonello R, Young J, et al. Osilodrostat, a potent oral 11b-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing\u2019s disease. Pituitary. 2016;19:138\u201348.","journal-title":"Pituitary"},{"key":"497_CR10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jchromb.2014.04.012","volume":"960","author":"W Li","year":"2014","unstructured":"Li W, Luo S, Rebello S, et al. A semi-automated LC-MS\/MS method for the determination of LCI699, a steroid 11\u03b2-hydroxylase inhibitor, in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;960:182\u201393.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"497_CR11","first-page":"307","volume":"65","author":"P Tomaszewski","year":"2008","unstructured":"Tomaszewski P, Kubiak-Tomaszewska G, Pachecka J. Cytochrome P450 polymorphism: molecular, metabolic, and pharmacogenetic aspects. II. Participation of CYP isoenzymes in the metabolism of endogenous substances and drugs. Acta Pol Pharm. 2008;65:307\u201318.","journal-title":"Acta Pol Pharm"},{"key":"497_CR12","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00216-008-2291-6","volume":"392","author":"UM Zanger","year":"2008","unstructured":"Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics\/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008;392:1093\u2013108.","journal-title":"Anal Bioanal Chem"},{"key":"497_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/00008571-199408000-00001","volume":"4","author":"PB Watkins","year":"1994","unstructured":"Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics. 1994;4:171\u201384.","journal-title":"Pharmacogenetics"},{"key":"497_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/00498250110102674","volume":"32","author":"GG Gibson","year":"2002","unstructured":"Gibson GG, Plant NJ, Swales KE, et al. Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica. 2002;32:165\u2013206.","journal-title":"Xenobiotica"},{"key":"497_CR15","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/0165-6147(92)90140-2","volume":"13","author":"S Cholerton","year":"1992","unstructured":"Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci. 1992;13:434\u20139.","journal-title":"Trends Pharmacol Sci"},{"key":"497_CR16","unstructured":"European Medicines Agency. Guideline on the investigation of drug interactions. 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/07\/WC500129606.pdf . Accessed 10 Jan 2017."},{"key":"497_CR17","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1177\/0091270007312153","volume":"48","author":"SM Huang","year":"2008","unstructured":"Huang SM, Strong JM, Zhang L, et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol. 2008;48:662\u201370.","journal-title":"J Clin Pharmacol"},{"key":"497_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/00008571-200004000-00001","volume":"10","author":"DS Streetman","year":"2000","unstructured":"Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics. 2000;10:187\u2013216.","journal-title":"Pharmacogenetics"},{"key":"497_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s40495-016-0059-9","volume":"2","author":"M Jamei","year":"2016","unstructured":"Jamei M. Recent advances in development and application of physiologically-based pharmacokinetic (PBPK) models: a transition from academic curiosity to regulatory acceptance. Curr Pharmacol Rep. 2016;2:161\u20139.","journal-title":"Curr Pharmacol Rep"},{"key":"497_CR20","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/clpt.2014.46","volume":"95","author":"V Sinha","year":"2014","unstructured":"Sinha V, Zhao P, Huang SM, Zineh I. Physiologically based pharmacokinetic modeling: from regulatory science to regulatory policy. Clin Pharmacol Ther. 2014;95:478\u201380.","journal-title":"Clin Pharmacol Ther"},{"key":"497_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/clpt.2010.298","volume":"89","author":"P Zhao","year":"2011","unstructured":"Zhao P, Zhang L, Grillo JA, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther. 2011;89:259\u201367.","journal-title":"Clin Pharmacol Ther"},{"key":"497_CR22","unstructured":"FDA. Guidance for industry. Drug interaction studies: study design, data analysis, implications for dosing, and labeling recommendations. 2012. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm292362.pdf . Accessed 10 Jan 2017."},{"key":"497_CR23","unstructured":"HRA Pharma. Ketoconazole HRA summary of product characteristics. 2015. http:\/\/www.medicines.org.uk\/emc\/medicine\/30077 . Accessed 10 Jan 2017."},{"key":"497_CR24","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1177\/0091270003259216","volume":"43","author":"YW Lam","year":"2003","unstructured":"Lam YW, Alfaro CL, Ereshefsky L, Miller M. Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol. 2003;43:1274\u201382.","journal-title":"J Clin Pharmacol"},{"key":"497_CR25","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1067\/mcp.2002.129068","volume":"72","author":"JI Lee","year":"2002","unstructured":"Lee JI, Chaves-Gnecco D, Amico JA, et al. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther. 2002;72:718\u201328.","journal-title":"Clin Pharmacol Ther"},{"key":"497_CR26","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/clpt.1994.60","volume":"55","author":"KT Olkkola","year":"1994","unstructured":"Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994;55:481\u20135.","journal-title":"Clin Pharmacol Ther"},{"key":"497_CR27","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0022-3565(24)38021-8","volume":"288","author":"K He","year":"1999","unstructured":"He K, Woolf TF, Hollenberg PF. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486). J Pharmacol Exp Ther. 1999;288:791\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"497_CR28","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1530\/EJE-10-0956","volume":"164","author":"NP Erp van","year":"2011","unstructured":"van Erp NP, Guchelaar HJ, Ploeger BA, et al. Mitotane has a strong and a durable inducing effect on CYP3A4 activity. Eur J Endocrinol. 2011;164:621\u20136.","journal-title":"Eur J Endocrinol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0497-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-017-0497-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0497-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T23:14:12Z","timestamp":1749942852000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-017-0497-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,2]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["497"],"URL":"https:\/\/doi.org\/10.1007\/s40261-017-0497-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,2]]}}}